Cargando…
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer with Peritoneal Metastasis—Indian Experience
Introduction Peritoneal metastasis secondary to gastric cancer is associated with poor prognosis. Recent studies have shown that cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) may be an efficacious treatment option for an otherwise palliative condition. Methods A...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718600/ https://www.ncbi.nlm.nih.gov/pubmed/36466973 http://dx.doi.org/10.1055/s-0041-1739176 |
_version_ | 1784843122033819648 |
---|---|
author | S.P, Somashekhar Karivedu, Jyothsana C., Rohit Kumar Y., Ramya Kapoor, Priya Rauthan, Amit K.R, Ashwin |
author_facet | S.P, Somashekhar Karivedu, Jyothsana C., Rohit Kumar Y., Ramya Kapoor, Priya Rauthan, Amit K.R, Ashwin |
author_sort | S.P, Somashekhar |
collection | PubMed |
description | Introduction Peritoneal metastasis secondary to gastric cancer is associated with poor prognosis. Recent studies have shown that cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) may be an efficacious treatment option for an otherwise palliative condition. Methods A retrospective single institutional study of patents diagnosed with gastric carcinoma and peritoneal metastasis and treated with CRS and HIPEC from February 2015 to December 2019. Results Sixteen patients with gastric cancer and peritoneal carcinomatosis were treated with CRS and HIPEC. Three patients underwent upfront surgery, and five patients underwent interval surgery. The mean peritoneal cancer index (PCI) was 3.5, and adequate complete cytoreduction (CC) score of 0/1 was achieved in all patients. All patients received HIPEC with mitomycin C. Major surgical complications were in 12.5% of patients. Grade I surgical site infection was present in one patient. Three patients had prolonged gastrointestinal (GI) recovery. The 30-day mortality was zero. Median follow-up time was 39 months. The median progression-free survival (PFS) was 12 months (95% confidence interval [CI] 6.86–17.13). The median overall survival (OS) was 17 months (95% CI 6.36–27.64). Conclusion Multidisciplinary treatment of perioperative chemotherapy with CRS and HIPEC is a promising treatment option, which may prolong survival in selected patients, and large randomized clinical trials are warranted for it to become standard of care. |
format | Online Article Text |
id | pubmed-9718600 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97186002022-12-03 Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer with Peritoneal Metastasis—Indian Experience S.P, Somashekhar Karivedu, Jyothsana C., Rohit Kumar Y., Ramya Kapoor, Priya Rauthan, Amit K.R, Ashwin South Asian J Cancer Introduction Peritoneal metastasis secondary to gastric cancer is associated with poor prognosis. Recent studies have shown that cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) may be an efficacious treatment option for an otherwise palliative condition. Methods A retrospective single institutional study of patents diagnosed with gastric carcinoma and peritoneal metastasis and treated with CRS and HIPEC from February 2015 to December 2019. Results Sixteen patients with gastric cancer and peritoneal carcinomatosis were treated with CRS and HIPEC. Three patients underwent upfront surgery, and five patients underwent interval surgery. The mean peritoneal cancer index (PCI) was 3.5, and adequate complete cytoreduction (CC) score of 0/1 was achieved in all patients. All patients received HIPEC with mitomycin C. Major surgical complications were in 12.5% of patients. Grade I surgical site infection was present in one patient. Three patients had prolonged gastrointestinal (GI) recovery. The 30-day mortality was zero. Median follow-up time was 39 months. The median progression-free survival (PFS) was 12 months (95% confidence interval [CI] 6.86–17.13). The median overall survival (OS) was 17 months (95% CI 6.36–27.64). Conclusion Multidisciplinary treatment of perioperative chemotherapy with CRS and HIPEC is a promising treatment option, which may prolong survival in selected patients, and large randomized clinical trials are warranted for it to become standard of care. Thieme Medical and Scientific Publishers Pvt. Ltd. 2021-12-31 /pmc/articles/PMC9718600/ /pubmed/36466973 http://dx.doi.org/10.1055/s-0041-1739176 Text en MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited. |
spellingShingle | S.P, Somashekhar Karivedu, Jyothsana C., Rohit Kumar Y., Ramya Kapoor, Priya Rauthan, Amit K.R, Ashwin Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer with Peritoneal Metastasis—Indian Experience |
title | Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer with Peritoneal Metastasis—Indian Experience |
title_full | Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer with Peritoneal Metastasis—Indian Experience |
title_fullStr | Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer with Peritoneal Metastasis—Indian Experience |
title_full_unstemmed | Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer with Peritoneal Metastasis—Indian Experience |
title_short | Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer with Peritoneal Metastasis—Indian Experience |
title_sort | cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis—indian experience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718600/ https://www.ncbi.nlm.nih.gov/pubmed/36466973 http://dx.doi.org/10.1055/s-0041-1739176 |
work_keys_str_mv | AT spsomashekhar cytoreductivesurgeryandhyperthermicintraperitonealchemotherapyingastriccancerwithperitonealmetastasisindianexperience AT karivedujyothsana cytoreductivesurgeryandhyperthermicintraperitonealchemotherapyingastriccancerwithperitonealmetastasisindianexperience AT crohitkumar cytoreductivesurgeryandhyperthermicintraperitonealchemotherapyingastriccancerwithperitonealmetastasisindianexperience AT yramya cytoreductivesurgeryandhyperthermicintraperitonealchemotherapyingastriccancerwithperitonealmetastasisindianexperience AT kapoorpriya cytoreductivesurgeryandhyperthermicintraperitonealchemotherapyingastriccancerwithperitonealmetastasisindianexperience AT rauthanamit cytoreductivesurgeryandhyperthermicintraperitonealchemotherapyingastriccancerwithperitonealmetastasisindianexperience AT krashwin cytoreductivesurgeryandhyperthermicintraperitonealchemotherapyingastriccancerwithperitonealmetastasisindianexperience |